UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis

Molecular oncology, 2024-03, Vol.18 (3), p.726-742

2024

Volltextzugriff (PDF)

BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients

Oncotarget, 2016-02, Vol.7 (5), p.6015-6028

2016

Volltextzugriff (PDF)

Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models

International journal of cancer, 2019-09, Vol.145 (5), p.1382-1394

2019

Volltextzugriff (PDF)

Abstract 1008: Comparative proteomics and transcriptomics analysis of the impact of androgen stimulation and darolutamide inhibition in a prostate cancer model

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1008-1008

2021

Volltextzugriff (PDF)

Abstract 1795: Darolutamide demonstrates greater in vivo activity than enzalutamide in prostate cancer model with therapy-resistant androgen receptor mutation

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1795-1795

2018

Volltextzugriff (PDF)

Abstract A028: In vitro and in vivo efficacy of the androgen receptor antagonist darolutamide in prostate cancer models

Cancer research (Chicago, Ill.), 2018-08, Vol.78 (16_Supplement), p.A028-A028

2018

Volltextzugriff (PDF)

Comparative Proteomic and Transcriptomic Analysis of the Impact of Androgen Stimulation and Darolutamide Inhibition

Cancers, 2022-12, Vol.15 (1), p.2

2022

Volltextzugriff (PDF)

Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and TAF1/TAF1L Bromodomains

Journal of medicinal chemistry, 2017-05, Vol.60 (9), p.4002-4022

2017

Volltextzugriff (PDF)

Abstract 651: Combination of the androgen receptor inhibitor darolutamide and the PI3K inhibitor copanlisib leads to improved anti-tumor efficacy and apoptosis in prostate cancer models

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.651-651

2022

Volltextzugriff (PDF)

Abstract 4691: Identification and characterization of BRPF1 bromodomain inhibitors

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.4691-4691

2016

Volltextzugriff (PDF)

Abstract B065: Combining the androgen receptor inhibitor darolutamide with PI3K/AKT/mTOR pathway inhibitors has superior efficacy in preclinical models of prostate cancer

Cancer research (Chicago, Ill.), 2023-06, Vol.83 (11_Supplement), p.B065-B065

2023

Volltextzugriff (PDF)

Abstract 980: BAY-299, a novel chemical probe for in-depth analysis of the function of the bromodomain proteins BRPF2 and TAF1

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.980-980

2017

Volltextzugriff (PDF)

Abstract 4703: The BET inhibitor BAY 1238097 shows efficacy in BRAF wild-type and mutant melanoma models

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.4703-4703

2016

Volltextzugriff (PDF)

Abstract 3524: BAY 1238097, a novel BET inhibitor with strong efficacy in hematological tumor models

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.3524-3524

2015

Volltextzugriff (PDF)

Abstract 1321: Castration-resistant prostate cancer: BAY 1024767 blocks function of mutated androgen receptor

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.1321-1321

2013

Volltextzugriff (PDF)

Differential mechanism for the cell surface sorting and agonist‐promoted internalization of the α 1B ‐adrenoceptor

British journal of pharmacology, 2009-02, Vol.124 (1), p.55-62

2009

Volltextzugriff (PDF)

Differential mechanism for the cell surface sorting and agonist‐promoted internalization of the α1B‐adrenoceptor

British journal of pharmacology, 1998-05, Vol.124 (1), p.55-62

1998

Volltextzugriff (PDF)

Differences in the subcellular localization of α1-adrenoceptor subtypes can affect the subtype selectivity of drugs in a study with the fluorescent ligand BODIPY FL-prazosin

Life sciences (1973), 2002-03, Vol.70 (18), p.2113-2124

2002

Volltextzugriff (PDF)

Differences in the subcellular localization of alpha1-adrenoceptor subtypes can affect the subtype selectivity of drugs in a study with the fluorescent ligand BODIPY FL-prazosin

Life sciences (1973), 2002-03, Vol.70 (18), p.2113-2124

2002

Volltextzugriff (PDF)

Differences in the subcellular localization of α 1-adrenoceptor subtypes can affect the subtype selectivity of drugs in a study with the fluorescent ligand BODIPY FL-prazosin

Life sciences (1973), 2002, Vol.70 (18), p.2113-2124

2002

Volltextzugriff (PDF)

Subtype-Specific Differences in Subcellular Localization of Î±1-Adrenoceptors: Chlorethylclonidine Preferentially Alkylates the Accessible Cell Surface Î±1-Adrenoceptors Irrespective of the Subtype

Molecular pharmacology, 1997-11, Vol.52 (5), p.764

1997

Volltextzugriff (PDF)

Subtype-Specific Differences in Subcellular Localization of α 1 -Adrenoceptors: Chlorethylclonidine Preferentially Alkylates the Accessible Cell Surface α 1 -Adrenoceptors Irrespective of the Subtype

Molecular pharmacology, 1997-11, Vol.52 (5), p.764-770

1997

Volltextzugriff (PDF)

Real-Time Optical Monitoring of Ligand-Mediated Internalization of α1b-Adrenoceptor with Green Fluorescent Protein

Molecular endocrinology (Baltimore, Md.), 1998-08, Vol.12 (8), p.1099-1111

1998

Volltextzugriff (PDF)

454. Basic Study of Gamma Correction in Bone Scintigraphy

Japanese Journal of Radiological Technology, 1990/08/01, Vol.46(8), pp.1425

1990

Volltextzugriff (PDF)

Crystallographic Texture of Melt-Spun Al-based Icosahedral Quasicrystals

Journal of the Japan Institute of Metals and Materials, 1991, Vol.55(6), pp.607-614

1991

Volltextzugriff (PDF)

1 – 25 von 183

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(132)
Mit Volltextzugriff
(163)

Publikationsform

Sprache

Englisch
(159)
Japanisch
(37)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis

BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients

Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models

Abstract 1008: Comparative proteomics and transcriptomics analysis of the impact of androgen stimulation and darolutamide inhibition in a prostate cancer model

Abstract 1795: Darolutamide demonstrates greater in vivo activity than enzalutamide in prostate cancer model with therapy-resistant androgen receptor mutation

Abstract A028: In vitro and in vivo efficacy of the androgen receptor antagonist darolutamide in prostate cancer models

Comparative Proteomic and Transcriptomic Analysis of the Impact of Androgen Stimulation and Darolutamide Inhibition

Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and TAF1/TAF1L Bromodomains

Abstract 651: Combination of the androgen receptor inhibitor darolutamide and the PI3K inhibitor copanlisib leads to improved anti-tumor efficacy and apoptosis in prostate cancer models

Abstract 4691: Identification and characterization of BRPF1 bromodomain inhibitors

Abstract B065: Combining the androgen receptor inhibitor darolutamide with PI3K/AKT/mTOR pathway inhibitors has superior efficacy in preclinical models of prostate cancer

Abstract 980: BAY-299, a novel chemical probe for in-depth analysis of the function of the bromodomain proteins BRPF2 and TAF1

Abstract 4703: The BET inhibitor BAY 1238097 shows efficacy in BRAF wild-type and mutant melanoma models

Abstract 3524: BAY 1238097, a novel BET inhibitor with strong efficacy in hematological tumor models

Abstract 1321: Castration-resistant prostate cancer: BAY 1024767 blocks function of mutated androgen receptor

Differential mechanism for the cell surface sorting and agonist‐promoted internalization of the α 1B ‐adrenoceptor

Differential mechanism for the cell surface sorting and agonist‐promoted internalization of the α1B‐adrenoceptor

Differences in the subcellular localization of α1-adrenoceptor subtypes can affect the subtype selectivity of drugs in a study with the fluorescent ligand BODIPY FL-prazosin

Differences in the subcellular localization of alpha1-adrenoceptor subtypes can affect the subtype selectivity of drugs in a study with the fluorescent ligand BODIPY FL-prazosin

Differences in the subcellular localization of α 1-adrenoceptor subtypes can affect the subtype selectivity of drugs in a study with the fluorescent ligand BODIPY FL-prazosin

Subtype-Specific Differences in Subcellular Localization of Î±1-Adrenoceptors: Chlorethylclonidine Preferentially Alkylates the Accessible Cell Surface Î±1-Adrenoceptors Irrespective of the Subtype

Subtype-Specific Differences in Subcellular Localization of α 1 -Adrenoceptors: Chlorethylclonidine Preferentially Alkylates the Accessible Cell Surface α 1 -Adrenoceptors Irrespective of the Subtype

Real-Time Optical Monitoring of Ligand-Mediated Internalization of α1b-Adrenoceptor with Green Fluorescent Protein

454. Basic Study of Gamma Correction in Bone Scintigraphy

Crystallographic Texture of Melt-Spun Al-based Icosahedral Quasicrystals

Suchergebnisse filtern